IL17RA and Miyoshi myopathy: To determine whether breaking the immune axis between IL-17 and eosinophils delayed disease progression, Early-MM Vk*MYC mice were treated with a cocktail of monoclonal antibodies directed against IL-17RA, IL-17A and IL-5 (Fig. 6a), the latter being relevant for activation, recruitment and survival of eosinophils42.